Tech Transfer in Cell & Gene Therapy
From Out of the Lab Podcast · 00:22:06
Show by Out of the Lab Media Group
In this episode, I'm joined by Brian Newsom, CEO of Carrigent. We discuss the challenges in effective tech transfer in the Cell and Gene Therapy industry. This includes effective documentation in CGT, why nuanced detail capture in SOPs is mission critical during tech transfer, and the different risk profiles of effective documentation between personalized medicine and generic drug production.
More episodes of Out of the Lab Podcast
More episodes
- When Supply Chain Becomes a Clinical Choice: Governance, Predictability, and the Patient Divide
- Solving the CGT Workforce Deficit & 50% CAR-T Attrition Gap | Dr. Shernan Holtan
- In Vivo Lenti, COGS Reduction, and the End Game Mindset with Ethan (Minaris)
- Rare Disease Commercialization: Lean Market Entry & Virtual Subsidiaries | Chad (ChangDeok) Ji
- Point-of-Care Bottlenecks, Portal Fatigue & SOP Ambiguity with Dr. Patrick Hanley
- Restoring Patient Agency: Breaking the 80% Access Barrier in Cell Therapy | Michelle Hill
- The 2 AM Audit Reality: Ex-FDA Regulators on CDMO Oversight, Night Shift Sins, and Data Integrity
- The $1M CDMO Selection Trap & Rethinking CMC Roadmaps with Shri Joshi
- Bunny Suits, Ice Buckets, and Slashing COGS: Bridging R&D and GMP Realities with Jerry (CellBri)
- What Cell & Gene Therapy Can Learn About Tech Transfer From Biofuels
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.